Cidara Therapeutics (CDTX) EBT: 2017-2025
Historic EBT for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to -$83.2 million.
- Cidara Therapeutics' EBT fell 435.78% to -$83.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$184.8 million, marking a year-over-year decrease of 361.27%. This contributed to the annual value of -$170.3 million for FY2024, which is 579.40% down from last year.
- Per Cidara Therapeutics' latest filing, its EBT stood at -$83.2 million for Q3 2025, which was down 223.64% from -$25.7 million recorded in Q2 2025.
- Over the past 5 years, Cidara Therapeutics' EBT peaked at $14.2 million during Q3 2022, and registered a low of -$83.2 million during Q3 2025.
- In the last 3 years, Cidara Therapeutics' EBT had a median value of -$8.2 million in 2024 and averaged -$21.1 million.
- In the last 5 years, Cidara Therapeutics' EBT skyrocketed by 178.78% in 2022 and then slumped by 540.68% in 2024.
- Over the past 5 years, Cidara Therapeutics' EBT (Quarterly) stood at -$16.8 million in 2021, then increased by 20.70% to -$13.3 million in 2022, then spiked by 38.66% to -$8.2 million in 2023, then crashed by 540.68% to -$52.4 million in 2024, then crashed by 435.78% to -$83.2 million in 2025.
- Its EBT was -$83.2 million in Q3 2025, compared to -$25.7 million in Q2 2025 and -$23.5 million in Q1 2025.